The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback